A multicenter study of costs of drugs in rheumatoid arthritis in China
- VernacularTitle:全国多中心类风湿关节炎患者门诊用药费用的调查
- Author:
Xiuru WANG
;
Yin SU
;
Yuan AN
;
Yunshan ZHOU
;
Lizhi WANG
;
Caihong WANG
;
Xiaofeng LI
;
Lina CHEN
;
Ping ZHU
;
Xin LU
;
Guochun WANG
;
Hongtao JIN
;
Rong YANG
;
Yongfu WANG
;
Guangtao LI
;
Zhuoli ZHANG
;
Lin SUN
;
Xiangyuan LIU
;
Jiemei TAO
;
Fengxiao ZHANG
;
Jing YANG
;
Zhenbin LI
;
Meiqiu WEI
;
Jinying LIN
;
Rong SHU
;
Liufu CUI
;
Dan KE
;
Xiaomin LIU
;
Cong YE
;
Shaoxian HU
;
Hao LI
;
Xiuyan YANG
;
Bei LAI
;
Ming GAO
;
Cibo HUANG
;
Lijun SONG
;
Xingfa LI
;
Zhanguo LI
- Publication Type:Journal Article
- Keywords: Arthritis,rheumatoid; Drug costs; Data collection
- From: Chinese Journal of Rheumatology 2010;14(6):368-372
- CountryChina
- Language:Chinese
- Abstract: Objective To describe the distribution of medication costs of rheumatoid arthritis patients, and to analyze the factors that may affect the costs. Methods Data were obtained from a 12-month retrospective investigation of patients with rheumatoid arthritis (RA) across China. Department of Rheuma-tology of 18 hospitals were randomly selected. The data about their social conditions, clinical conditions, medications associated with RA such as disease-modifying antirheumatic drugs (DMARDs), non -steroidal anti -inflammtory drugs (NSAIDs), steroids, biologic agents were collected, and the costs of drugs were calculated. A non-parameter test and multivariate logistic regression analysis were performed. Results Six hundred and forty six patients were enrolled into the study, 435 completed data were chosen for analysis. The results demonstrated that the average costs per patient for medications in the past year was 8018 . The total medication costs were further subdivided into the following parts: DMARDs, (represented 20% of the total costs), biologic drugs (49%), NSAIDs (4%), herbal drugs (22%), steroids (1%). Data analysis showed that patients with higher education and higher incomes, with medical insurance,better health function status and outpatients paid more on DMARDs. Extra-articular manifestations increased the odds of the high-cost group (OR: 2.180, 95%CI: 1.335～3.558, P=0.002), while poor health function status increased the probability of paying high costs (OR: 1.373, 95%CI: 1.012～1.863, P=0.041). Conclusion High medication costs in RA do exist in RA patients. The costs of medication is associated with health function status and the presence of extra-articular manifestations.